MedPath

Oral Formulation of Insulin for Preterm Infants

Phase 2
Terminated
Conditions
Premature Birth of Newborn
Interventions
Biological: Oral Formulation of Insulin
Biological: Placebo
Registration Number
NCT01093638
Lead Sponsor
Elgan Pharma Ltd.
Brief Summary

The study will evaluate the effect of oral formulation of insulin on preterm infants, born between 26-33 weeks of pregnancy, weighing over 750 grams, who meet the inclusion and exclusion criteria established in this protocol.

Detailed Description

The study will aim to determine whether an oral formulation of insulin administration enhances gastrointestinal maturation. The gastrointestinal maturation will be evaluated by the ability of premature infants to achieve complete enteral feeds. The insulin concentration administered in the study is physiological and within the insulin concentration range present in human breast milk and colostrum.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
33
Inclusion Criteria
  1. Pre-term infants 26-33 weeks gestation.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Oral Formulation of InsulinOral Formulation of InsulinOral formulation of insulin fed concomitantly with premature infant formula
Oral Formulation of PlaceboPlaceboOral formulation of placebo fed concomitantly with premature infant formula
Primary Outcome Measures
NameTimeMethod
Number of days to achieve complete enteral feedingUp to 28 days or discharge and at 3 months of age
Secondary Outcome Measures
NameTimeMethod
Number of gastric residual > 2 ml/kgUp to 28 days or discharge, at 3 months of age
Number of days to dischargeUp to 28 days or discharge and at 3 months of age
Number of gastric residual > 50% of previous feedingUp to 28 days or discharge and at 3 months of age
Weight gainUp to 28 days or discharge and at 3 months of age

Trial Locations

Locations (1)

NICU, Laniado Hospital

🇮🇱

Netanya, Israel

© Copyright 2025. All Rights Reserved by MedPath